CN114585387B - 利用联用药物的糖尿病的治疗或预防方法 - Google Patents

利用联用药物的糖尿病的治疗或预防方法 Download PDF

Info

Publication number
CN114585387B
CN114585387B CN202080076112.9A CN202080076112A CN114585387B CN 114585387 B CN114585387 B CN 114585387B CN 202080076112 A CN202080076112 A CN 202080076112A CN 114585387 B CN114585387 B CN 114585387B
Authority
CN
China
Prior art keywords
compound
formula
minutes
acid
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080076112.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114585387A (zh
Inventor
米良泰子
胜见壮平
大熊千寻
持田诚也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to CN202411355046.5A priority Critical patent/CN119113123A/zh
Publication of CN114585387A publication Critical patent/CN114585387A/zh
Application granted granted Critical
Publication of CN114585387B publication Critical patent/CN114585387B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080076112.9A 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法 Active CN114585387B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411355046.5A CN119113123A (zh) 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019161526 2019-09-04
JP2019-161526 2019-09-04
PCT/JP2020/033463 WO2021045159A1 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411355046.5A Division CN119113123A (zh) 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法

Publications (2)

Publication Number Publication Date
CN114585387A CN114585387A (zh) 2022-06-03
CN114585387B true CN114585387B (zh) 2024-10-29

Family

ID=74852211

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080076112.9A Active CN114585387B (zh) 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法
CN202411355046.5A Pending CN119113123A (zh) 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411355046.5A Pending CN119113123A (zh) 2019-09-04 2020-09-03 利用联用药物的糖尿病的治疗或预防方法

Country Status (10)

Country Link
US (1) US20230119894A1 (cg-RX-API-DMAC7.html)
EP (2) EP4026564A4 (cg-RX-API-DMAC7.html)
JP (2) JP7692832B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220056219A (cg-RX-API-DMAC7.html)
CN (2) CN114585387B (cg-RX-API-DMAC7.html)
AU (1) AU2020341926B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003323A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151909A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002683A (cg-RX-API-DMAC7.html)
WO (1) WO2021045159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure
MX2023013662A (es) * 2021-09-02 2024-01-08 Daewoong Therapeutics Inc Composicion farmaceutica para prevenir o tratar una enfermedad ocular diabetica que comprende el inhibidor de sglt-2.
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917535A (zh) * 2011-08-31 2014-07-09 日本烟草产业株式会社 吡唑化合物和其药物用途
CN104284894A (zh) * 2012-05-10 2015-01-14 伊莱利利公司 新型吡唑化合物
WO2019168096A1 (ja) * 2018-03-01 2019-09-06 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
CN114641314A (zh) * 2019-09-04 2022-06-17 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917535A (zh) * 2011-08-31 2014-07-09 日本烟草产业株式会社 吡唑化合物和其药物用途
CN104284894A (zh) * 2012-05-10 2015-01-14 伊莱利利公司 新型吡唑化合物
WO2019168096A1 (ja) * 2018-03-01 2019-09-06 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
CN111757877A (zh) * 2018-03-01 2020-10-09 日本烟草产业株式会社 甲基内酰胺环化合物及其药物用途
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
CN111902408A (zh) * 2018-04-04 2020-11-06 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途
CN114641314A (zh) * 2019-09-04 2022-06-17 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法

Also Published As

Publication number Publication date
KR20220056219A (ko) 2022-05-04
JP7692832B2 (ja) 2025-06-16
US20230119894A1 (en) 2023-04-20
EP4026564A4 (en) 2023-03-15
BR112022003323A2 (pt) 2022-05-24
JPWO2021045159A1 (cg-RX-API-DMAC7.html) 2021-03-11
WO2021045159A1 (ja) 2021-03-11
EP4026564A1 (en) 2022-07-13
AU2020341926A1 (en) 2022-03-17
MX2022002683A (es) 2022-04-07
JP2025094217A (ja) 2025-06-24
CN114585387A (zh) 2022-06-03
CA3151909A1 (en) 2021-03-11
AU2020341926B2 (en) 2026-02-26
EP4342466A1 (en) 2024-03-27
CN119113123A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
CN119113123A (zh) 利用联用药物的糖尿病的治疗或预防方法
TWI805727B (zh) 經雜芳基取代之吡唑化合物及其醫藥用途
CN111757877B (zh) 甲基内酰胺环化合物及其药物用途
US20250084056A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
JP2025138791A (ja) 慢性腎臓病の治療又は予防方法
RU2857384C2 (ru) Способ лечения или профилактики диабета с помощью комбинированной медицины
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
HK40068410A (en) Chronic kidney disease treatment or prevention method
HK40044833A (en) Methyllactam ring compound and medicinal use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant